Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The Antiaging Protein Klotho Enhances Oligodendrocyte Maturation and Myelination of the CNS.
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Discontinuation of Disease-Modifying Treatment for Multiple Sclerosis
Title: Pharmacokinetics and Pharmacodynamics of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis in the Randomised ADVANCE Study.
Rituximab in paediatric onset multiple sclerosis: a case series.
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis.
Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C.
IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features.
Receptos initiates clinical trials for S1P1 agonist program, aimed at multiple sclerosis
Cladribine
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
Cognitive impairment in multiple sclerosis.
Enzon presents pre-clinical data on controlled release of PEGylated interferon-beta-1b and PEGylated anti-TNF-a antibody fragment at the Controlled Release Society annual meeting
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Differential roles of microglia and monocytes in the inflamed central nervous system.
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Decreased microglial activation in MS patients treated with glatiramer acetate.
Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics.
Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.

Pages